Parlodel treatment of uremic hypogonadism in men.
Parlodel, 2.5 mg daily, was given during 1-3 months to 14 uremic hypogonadal patients (placebo controlled in 6). Except for a decrease in serum prolactin levels on Parlodel (p less than 0.01), no significant changes in hormonal values (gonadotropins and testosterone) were observed either on Parlodel or on placebo. Parlodel treatment improved the potency of 10 patients, eliminated gynecomastia in 2 and normalized spermatogenesis in 6; the best results were obtained in patients on low-protein diet. On placebo, potency improved only in 1 patient; no improvement in spermatogenesis was registered. Thus, Parlodel can improve sexual function and spermatogenesis in hypogonadal uremic males.
Ermolenko
V M
VM
Kukhtevich
A V
AV
Dedov
I I
II
Bunatian
A F
AF
Melnichenko
G A
GA
Gitel
E P
EP
D000328:Adult; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D004044:Dietary Proteins / Q000008:administration & dosage; D004311:Double-Blind Method; D005640:Follicle Stimulating Hormone / Q000097:blood; D006177:Gynecomastia / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007989:Libido / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects; D011388:Prolactin / Q000097:blood; D013091:Spermatogenesis / Q000187:drug effects*; D013739:Testosterone / Q000097:blood; D014511:Uremia / Q000150:complications / Q000628:therapy
D004044:Dietary Proteins; D001971:Bromocriptine; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone